Showing 1 - 9 of 9
This paper examines the determinants of M&A activity in the pharmaceutical-biotechnology industry and the effects of mergers using propensity scores to control for merger endogeneity. Among large firms, we find that mergers are a response to excess capacity due to anticipated patent expirations...
Persistent link: https://www.econbiz.de/10005084775
We examine the determinants and effects of M&A activity in the pharmaceutical|biotechnology industry using SDC data on 383 firms from 1988 to 2001. For large firms, mergers are a response to expected excess capacity due to patent expirations and gaps in a firm's product pipeline. For small...
Persistent link: https://www.econbiz.de/10005209337
Persistent link: https://www.econbiz.de/10010212756
Persistent link: https://www.econbiz.de/10006963396
Persistent link: https://www.econbiz.de/10007764379
Persistent link: https://www.econbiz.de/10003543650
Persistent link: https://www.econbiz.de/10002104576
Persistent link: https://www.econbiz.de/10002527935
This paper examines the determinants of M&A activity in the pharmaceutical-biotechnology industry and the effects of mergers using propensity scores to control for merger endogeneity. Among large firms, we find that mergers are a response to excess capacity due to anticipated patent expirations...
Persistent link: https://www.econbiz.de/10012468157